Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-975"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-975"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-1952
lpv:speaker	lp:Françoise Castex2
lpv:spokenAs	substitute; EMPL (2009-07-16--2012-01-18)3 member; JURI (2009-07-16--2012-01-18)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 unknown; Parti socialiste (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3
lpv:translated text	"I voted in favour of this report because it seems unacceptable to me to want to make pathetically low savings on patient safety and product quality. The European Commission’s initial proposals led to a weakening of the current system by giving a central role to companies for listing, alerting, analysing and providing information as regards their medicines’ side effects. However, the cornerstone of efficiency and safety for patients is the independence of pharmacovigilance networks and committees. The compromise with the Council contains improvements in terms of transparency and, more importantly, it prevents inadequately tested medicines from being put on the market, as the European Commission was initially proposing."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph